Barclays Cuts Estimates on Par Pharmaceutical (PRX); Removing Lovaza Contribution From Model

May 31, 2012 2:11 PM EDT Send to a Friend
Get Alerts PRX Hot Sheet
Price: $49.98 --0%

Rating Summary:
    2 Buy, 8 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 24 | Down: 14 | New: 40
Trade PRX Now!
Join SI Premium – FREE
Barclays maintains an 'Equalweight' on Par Pharmaceutical (NYSE: PRX) price target of $35.00.

Analyst, Douglas D. Tsao, said, "We our removing a generic Lovaza contribution from our 2012-2016 estimates and now assume no contribution until patent expiry in 2017. Our revised EPS estimates are as follows: 2012 - $3.70 vs previous $3.85; 2013 - $2.92 vs previous $3.26; 2014 - $3.29 vs previous $4.24; 2015 - $3.46 vs previous $3.91; 2016 - $4.80 vs previous $5.25."

For an analyst ratings summary and ratings history on Par Pharmaceutical click here. For more ratings news on Par Pharmaceutical click here.

Shares of Par Pharmaceutical closed at $37.01 yesterday.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Analyst EPS Change, Analyst EPS View

Related Entities

Barclays

Add Your Comment